Eli Lilly and Company (NYSE:LLY) Receives $858.72 Consensus PT from Analysts

Eli Lilly and Company (NYSE:LLYGet Free Report) has been given a consensus rating of “Moderate Buy” by the eighteen research firms that are covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $893.00.

LLY has been the subject of a number of research reports. BMO Capital Markets reissued an “outperform” rating and issued a $1,001.00 price target on shares of Eli Lilly and Company in a research note on Wednesday, July 3rd. Barclays raised their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday. Truist Financial reissued a “buy” rating and set a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Finally, Bank of America reaffirmed a “buy” rating and issued a $1,000.00 target price on shares of Eli Lilly and Company in a research note on Monday, June 24th.

Get Our Latest Stock Analysis on Eli Lilly and Company

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the transaction, the chief accounting officer now owns 7,130 shares in the company, valued at $5,842,821.10. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the transaction, the insider now owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the completion of the transaction, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,214,704 shares of company stock worth $1,066,841,316. 0.13% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Rock Point Advisors LLC purchased a new stake in Eli Lilly and Company in the second quarter worth $282,000. Wilkins Investment Counsel Inc. boosted its holdings in shares of Eli Lilly and Company by 8.4% during the 2nd quarter. Wilkins Investment Counsel Inc. now owns 3,104 shares of the company’s stock valued at $2,810,000 after buying an additional 240 shares in the last quarter. Diversify Wealth Management LLC purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter worth about $4,067,000. Seven Mile Advisory increased its stake in shares of Eli Lilly and Company by 4.0% in the 2nd quarter. Seven Mile Advisory now owns 1,136 shares of the company’s stock worth $1,028,000 after acquiring an additional 44 shares in the last quarter. Finally, Vista Capital Partners Inc. increased its stake in shares of Eli Lilly and Company by 5.7% in the 2nd quarter. Vista Capital Partners Inc. now owns 1,069 shares of the company’s stock worth $968,000 after acquiring an additional 58 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 9.4 %

LLY stock opened at $844.57 on Friday. The company’s 50 day moving average is $869.64 and its 200 day moving average is $792.50. The stock has a market cap of $802.68 billion, a price-to-earnings ratio of 124.38, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 1-year low of $516.57 and a 1-year high of $966.10.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.62%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

About Eli Lilly and Company

(Get Free Report

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Stories

Analyst Recommendations for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.